Targeting Nav1.5 trafficking as a therapy for lethal genetic cardiac arrhythmias

以 Nav1.5 贩运为目标作为致命遗传性心律失常的治疗方法

基本信息

  • 批准号:
    9041020
  • 负责人:
  • 金额:
    $ 39.62万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2015
  • 资助国家:
    美国
  • 起止时间:
    2015-04-01 至 2019-03-31
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): Cardiac arrhythmias cause more than 400,000 sudden deaths each year in the U.S. Mutations in the cardiac sodium channel gene SCN5A cause several inherited arrhythmias, including Brugada syndrome (BrS) and sick sinus syndrome (SSS). SCN5A encodes the cardiac sodium channel Nav1.5, which produces the cardiac sodium current (INa) responsible for generation and propagation of the cardiac action potential. BrS and SSS mutations in SCN5A act by a loss of function mechanism (i.e. loss or reduction of INa). Reduction of INa is associated with defective trafficking of Nav1.5 to the plasma membrane. However, the molecular mechanisms underlying trafficking of Nav1.5 to the plasma membrane are mostly unknown. To identify critical molecular determinants required for Nav1.5 trafficking, we performed a yeast two-hybrid screen and identified a small protein MOG1 that interacts directly with Nav1.5 and can facilitate trafficking of Nav1.5 to the plasma membrane and increase INa. One dominant negative mutation of MOG1 (E83D) was reported in BrS and also causes a trafficking defect of Nav1.5 and reduced INa. We have found that MOG1 is required for ER export of Nav1.5 during trafficking. Computer-based protein structural modeling followed by protein-protein interaction studies indicate that MOG1 interacts with Sar1-GTPase, one of the most important proteins regulating ER export. Based on these novel findings, we hypothesize that MOG1 regulates ER export of Nav1.5 by regulating the Sar1-GTP cycle. Interestingly, we have found that overexpression of MOG1 in HEK293/tsA201 cells can fully rescue the reduced INa caused by trafficking defects of BrS mutation G1743R and SSS mutation D1275N in SCN5A. We surmise that overexpression of MOG1 can rescue trafficking defects of Nav1.5 mutations causing BrS and SSS in animal models containing mutations G1743R and D1275N as well as heterozygous Scn5a+/- mice (an existing model for BrS). Thus, in this project we will first determine whether overexpression of MOG1 by adeno- associated virus-mediated gene transfer can rescue the trafficking defects of Nav1.5 mutations G1743R and D1275N and attenuate related disease phenotypes in mouse models for BrS and SSS (Aim 1). Currently, no effective therapies exist for BrS or SSS except for invasive implantation of ICDs (Implantable Cardioverter Defibrillators) or pacemakers, respectively. Due to the invasiveness and many side effects associated with ICDs and pacemakers, we believe that the development of a non-invasive therapy, i.e. a novel MOG1- based gene therapy, is highly valuable for human patients. Then, we will utilize a series of integrative biochemical, molecular biological and cellular approaches to identify the molecular mechanisms by which MOG1 controls trafficking of Nav1.5 to cell surface (Aim 2), which may be used to enhance the efficacy of MOG1 gene therapy for BrS and SSS.
 描述(由申请人提供):在美国,心律失常每年导致超过 400,000 例猝死。心脏钠通道基因 SCN5A 的突变会导致多种遗传性心律失常,包括布鲁格达综合征 (BrS) 和病态窦房结综合征 (SSS)。 SCN5A 编码心脏钠通道 Nav1.5,它产生心脏钠电流 (INa),负责心脏动作电位的产生和传播。 SCN5A 中的 BrS 和 SSS 突变通过功能丧失机制(即 INa 丢失或减少)起作用。 INa 的减少与 Nav1.5 向质膜运输的缺陷有关。然而,Nav1.5 运输至质膜的分子机制大多未知。为了确定 Nav1.5 运输所需的关键分子决定因素,我们进行了酵母双杂交筛选,并鉴定了一种小蛋白 MOG1,它直接与 Nav1.5 相互作用,可以促进 Nav1.5 运输到质膜并增加 INa。据报道,BrS 中存在 MOG1 (E83D) 的一种显性失活突变,该突变也会导致 Nav1.5 的运输缺陷和 INa 减少。我们发现,在贩运过程中,MOG1 是 Nav1.5 的 ER 导出所必需的。基于计算机的蛋白质结构建模以及蛋白质-蛋白质相互作用研究表明 MOG1 与 Sar1-GTPase 相互作用,Sar1-GTPase 是调节 ER 输出的最重要的蛋白质之一。基于这些新发现,我们假设 MOG1 通过调节 Sar1-GTP 循环来调节 Nav1.5 的 ER 输出。 有趣的是,我们发现在HEK293/tsA201细胞中过表达MOG1可以完全挽救SCN5A中BrS突变G1743R和SSS突变D1275N运输缺陷引起的INa减少。我们推测,MOG1 的过度表达可以挽救含有突变 G1743R 和 D1275N 的动物模型以及杂合子 Scn5a+/- 小鼠(BrS 的现有模型)中导致 BrS 和 SSS 的 Nav1.5 突变的运输缺陷。 因此,在本项目中,我们将首先确定通过腺相关病毒介导的基因转移过度表达 MOG1 是否可以挽救 Nav1.5 突变 G1743R 和 D1275N 的运输缺陷,并减轻 BrS 和 SSS 小鼠模型中的相关疾病表型(目标 1)。目前,除了侵入性植入 ICD(植入式心脏复律除颤器)或起搏器外,尚无针对 BrS 或 SSS 的有效疗法。由于 ICD 和起搏器具有侵入性和许多副作用,我们相信开发一种非侵入性疗法,即一种新型的基于 MOG1 的基因疗法,对人类患者非常有价值。然后,我们将利用一系列综合生化、分子生物学和细胞方法来确定MOG1控制Nav1.5向细胞表面运输的分子机制(目标2),这可能用于增强MOG1基因治疗BrS和SSS的疗效。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

QING Kenneth WANG其他文献

QING Kenneth WANG的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('QING Kenneth WANG', 18)}}的其他基金

Targeting Nav1.5 trafficking as a therapy for lethal genetic cardiac arrhythmias
以 Nav1.5 贩运为目标作为致命遗传性心律失常的治疗方法
  • 批准号:
    9243290
  • 财政年份:
    2015
  • 资助金额:
    $ 39.62万
  • 项目类别:
Targeting Nav1.5 trafficking as a therapy for lethal genetic cardiac arrhythmias
以 Nav1.5 贩运为目标作为致命遗传性心律失常的治疗方法
  • 批准号:
    8859323
  • 财政年份:
    2015
  • 资助金额:
    $ 39.62万
  • 项目类别:
NGS in Large CAD Families: In-Depth Identification of Rare Risk Genomic Variants
大型 CAD 家族中的 NGS:深入鉴定罕见风险基因组变异
  • 批准号:
    8762112
  • 财政年份:
    2014
  • 资助金额:
    $ 39.62万
  • 项目类别:
NGS in Large CAD Families: In-Depth Identification of Rare Risk Genomic Variants
大型 CAD 家族中的 NGS:深入鉴定罕见风险基因组变异
  • 批准号:
    9053995
  • 财政年份:
    2014
  • 资助金额:
    $ 39.62万
  • 项目类别:
Novel Role of a Nucleoporin Gene in Atrial Fibrillation, the Most Common Cardiac
核孔蛋白基因在心房颤动(最常见的心脏疾病)中的新作用
  • 批准号:
    8063582
  • 财政年份:
    2010
  • 资助金额:
    $ 39.62万
  • 项目类别:
Novel Role of a Nucleoporin Gene in Atrial Fibrillation, the Most Common Cardiac
核孔蛋白基因在心房颤动(最常见的心脏疾病)中的新作用
  • 批准号:
    8242821
  • 财政年份:
    2010
  • 资助金额:
    $ 39.62万
  • 项目类别:
Novel Role of a Nucleoporin Gene in Atrial Fibrillation, the Most Common Cardiac
核孔蛋白基因在心房颤动(最常见的心脏疾病)中的新作用
  • 批准号:
    7887117
  • 财政年份:
    2010
  • 资助金额:
    $ 39.62万
  • 项目类别:
Novel Role of a Nucleoporin Gene in Atrial Fibrillation, the Most Common Cardiac
核孔蛋白基因在心房颤动(最常见的心脏疾病)中的新作用
  • 批准号:
    8442341
  • 财政年份:
    2010
  • 资助金额:
    $ 39.62万
  • 项目类别:
PREMATURE MYOCARDIAL INFARCTION LOCUS ON CHROMOSOME 1P34-36
染色体 1P34-36 上的过早心肌梗塞位点
  • 批准号:
    7181293
  • 财政年份:
    2005
  • 资助金额:
    $ 39.62万
  • 项目类别:
CHROMOSOME 1 LOCUS FOR PREMATURE MYOCARDIAL INFARCTION
早期心肌梗死的 1 号染色体位点
  • 批准号:
    6977704
  • 财政年份:
    2004
  • 资助金额:
    $ 39.62万
  • 项目类别:

相似海外基金

Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
  • 批准号:
    10591918
  • 财政年份:
    2023
  • 资助金额:
    $ 39.62万
  • 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
  • 批准号:
    23K15383
  • 财政年份:
    2023
  • 资助金额:
    $ 39.62万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
  • 批准号:
    23H03556
  • 财政年份:
    2023
  • 资助金额:
    $ 39.62万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
  • 批准号:
    23K17212
  • 财政年份:
    2023
  • 资助金额:
    $ 39.62万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
  • 批准号:
    22H03519
  • 财政年份:
    2022
  • 资助金额:
    $ 39.62万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
  • 批准号:
    563657-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 39.62万
  • 项目类别:
    Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10521849
  • 财政年份:
    2022
  • 资助金额:
    $ 39.62万
  • 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10671022
  • 财政年份:
    2022
  • 资助金额:
    $ 39.62万
  • 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
  • 批准号:
    10670918
  • 财政年份:
    2022
  • 资助金额:
    $ 39.62万
  • 项目类别:
Downsides of downhill: The adverse effects of head vibration associated with downhill mountain biking on visuomotor and cognitive function
速降的缺点:与速降山地自行车相关的头部振动对视觉运动和认知功能的不利影响
  • 批准号:
    2706416
  • 财政年份:
    2022
  • 资助金额:
    $ 39.62万
  • 项目类别:
    Studentship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了